Meeting
2021 ASCO Annual Meeting
Prevalence of inferred clonal hematopoiesis (CH) detected on comprehensive genomic profiling (CGP) of solid tumor tissue or circulating tumor DNA (ctDNA).
Authors
Emmanuel S. Antonarakis
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Emmanuel S. Antonarakis , Zheng Kuang , Hanna Tukachinsky , Christine Parachoniak , Andrew David Kelly , Ole Gjoerup , Aparna Aiyer , Eric Allan Severson , Dean C. Pavlick , Garrett M. Frampton , Jeffrey Michael Venstrom , Geoffrey R. Oxnard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3009)
DOI
10.1200/JCO.2021.39.15_suppl.3009
Abstract #
3009
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2023 ASCO Quality Care Symposium
CHIPping in: Clonal hematopoiesis clinics in community oncology.
First Author: Michael Byrne
Poster
2019 ASCO Annual Meeting
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.
First Author: Madison Conces